Showing results (71-80 of 142) with videos related to

Sort By:
Pageof 15
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2020
Evaluation of Montelukast for the Prevention of Infusion-related Reactions With DaratumumabDonald C Moore, Justin R Arnall, Daniel L Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myelomaPeter M Voorhees, Qing Chen, Deborah J Kuhn, et al.
American Journal of Hematology|June 27, 2024
Hereditary chronic neutrophilic leukemia in a four-generation family without transformation to acute leukemiaAmanda Lance, Zane Chiad, Sara L Seegers, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 14, 2020
Safety and Cost Benefits of the Rapid Daratumumab Infusion ProtocolIssam S Hamadeh, Emily S Reese, Justin R Arnall, et al.
Blood Advances|February 19, 2021
Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFINPeter M Voorhees, Cesar Rodriguez, Brandi Reeves, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2021
Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical PracticeIssam S Hamadeh, Donald C Moore, Allison Martin, et al.
Blood Cancer Journal|March 22, 2019
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I studySuzanne Trudel, Nikoletta Lendvai, Rakesh Popat, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 28, 2022
Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple MyelomaDavid M Foureau, Barry A Paul, Fei Guo, et al.
The Lancet. Haematology|September 3, 2017
Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trialsManisha Bhutani, Qing Zhang, Reed Friend, et al.
American Journal of Hematology|September 24, 2021
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)Peter M Voorhees, Vera J Suman, Sascha A Tuchman, et al.
Pageof 15